The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
Ibuprofen and Famotidine tablets approved by FDA
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
